查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363926

全球子宮頸肌張力失調治療市場 2023-2030

Global Cervical Dystonia Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

預計全球頸部肌張力失調治療市場在預測期內將以 7.8% 的年複合成長率成長。頸部肌張力失調是一種神經系統疾病，會導致頸部肌肉不自主收縮。這可能會導致頭部向一側傾斜或扭曲，或下巴向上、向下、向前或向後拉。推動市場成長的主要因素包括頸部肌張力失調的盛行率不斷增加。據國家罕見疾病組織 (NORD) 稱，美國估計有 60,000 人患有頸部肌張力失調。此外，估計全球每 10 萬人中有 5 至 30 例。由於這些因素，對頸部肌張力失調的有效治療的需求顯著增加。肉毒桿菌注射/藥物被認為是最有效且耐受性良好的治療方法。然而，新的和創新的治療方法已經取得了一些進展，例如深部腦部刺激（DBS）、幹細胞療法、基因療法等。

細分市場前景

全球頸部肌張力失調治療市場根據藥物類型、應用和最終用戶類型進行細分。依藥物類型，市場分為肉毒桿菌、抗膽鹼能藥物、多巴胺能藥物等。根據應用，市場分為醫院藥局、零售藥局、網路藥局等。根據最終用戶，市場分為醫院、診所和其他。在申請中，醫院藥局預計將佔據相當大的市場佔有率，因為大多數用於治療頸部肌張力失調的藥物均未獲授權銷售。

肉毒桿菌毒素藥物類型將主導全球子宮頸肌張力失調治療市場

在藥物類型中，肉毒桿菌細分市場預計將佔據顯著的市場佔有率。由於其高效性和安全性，它是治療頸部肌張力失調最常用的藥物。因此，全球範圍內肉毒桿菌毒素藥物的開發和核准活動持續穩定。例如，2021年，美國FDA批准了一種名為Daxxify的新型肉毒桿菌藥物。它是一種更有效的肉毒桿菌毒素，已被證明比舊的肉毒桿菌毒素藥物在治療頸部肌張力失調方面更有效。此類批准活動將導致更多地採用肉毒毒素注射和藥物作為頸部肌張力失調的有效治療方法。

區域展望

全球頸部肌張力失調治療市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（義大利、西班牙、德國、法國等）、亞太地區（印度、中國、日本、韓國、等）以及世界其他地區（中東、非洲和拉丁美洲）。其中，由於北美擁有完善的頸部肌張力失調治療研究機構和醫院，預計將主導市場。

歐洲地區將在全球子宮頸肌張力失調市場中佔據顯著佔有率

在所有地區中，預計歐洲地區將在全球頸部肌張力失調市場中佔據相當大的佔有率。這一成長主要是由於該地區頸部肌張力失調盛行率上升。據英國肌張力失調組織稱，最常見的肌張力失調是頸部肌張力失調，影響英國約 18,000 名成年人。因此，各種策略措施的採用顯著增加，例如合作和合併等，以透過提供有效的治療來減少整個地區頸部肌張力失調的數量。例如，2023 年 8 月，IPSEN 宣布與 Dystonia Europe 合作，協助發現頸部肌張力失調患者未滿足的需求。該計畫包括共同創建首個頸部肌張力失調患者體驗圖，該地圖發表在《Orphanet 罕見疾病雜誌》上，該地圖記錄了英國、法國和義大利15 名頸肌肌張力失調患者從最初診斷到生活的經歷。與日常的情況。

市場參與者展望

服務全球頸部肌張力失調治療市場的主要公司包括艾伯維公司（AbbVie Inc.）、易普森製藥公司（Ipsen Pharma）、Merz Pharma GmbH & Co.KGaA.、Revance Therapeutics, Inc.、Hint, Inc.和USWM, LLC 等。市場參與者透過各種策略（包括併購、合作、合作和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2023 年 8 月，美國食品藥物管理局批准 Daxxify（DaxibotulinumtoxinA-lanm；Revance Therapeutics，納許維爾，田納西州）作為其第一個注射治療適應症，用於治療成人頸部肌張力失調。

報告涵蓋：

  • 2022年市場價​​值資料分析及2030年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 全球頸部肌張力失調治療市場的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵細分市場來分析業務策略。
  • 市場進入和市場擴張策略分析。
  • 透過識別市場中「誰的立場」來制定競爭策略。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • AbbVie Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Ipsen Pharma
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Merz Pharma GmbH & Co.KGaA.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Revance Therapeutics, Inc., Hint, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • USWM, LLC
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按藥物類型分類的全球子宮頸肌張力失調治療市場
    • 肉毒桿菌毒素
    • 抗膽鹼能藥物
    • 多巴胺能藥物
    • 其他
  • 全球子宮頸肌張力失調治療市場（按應用）
    • 醫院藥房
    • 零售藥房
    • 網路藥房
    • 其他（專營藥局）
  • 全球子宮頸肌張力失調治療市場（按最終用戶）
    • 醫院
    • 診所
    • 其他（臨床研究機構）

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Addex Pharma SA
  • Akorn Inc
  • Almirall, S.A.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • BIOGEN INC.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • DAIICHI SANKYO Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Galderma S.A.
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • Lannett Co., Inc.
  • Mylan Pharmaceutical Pvt. Ltd.
  • Novartis AG.
  • Pfizer Inc.
  • Piramal Grp.
  • SANOFI
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Ind., Ltd.
  • Teva Pharmaceutical Ind., Ltd.
  • UCB Biopharma SRL.
Product Code: OMR2027701

Title: Global Cervical Dystonia Treatment Market Size, Share & Trends Analysis Report Market by Drug Type (Botulinum toxin, Anticholinergic agents, Dopaminergic agents, and Others), by Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), and by End-User (Hospitals, Clinics, and Others)Forecast Period (2023-2030).

The global cervical dystonia treatment market is anticipated to grow at a considerable CAGR of 7.8% during the forecast period. Cervical dystonia is a neurological disorder that causes the muscles in the neck to contract involuntarily. This can cause the head to lean or twist to one side, or the chin to pull up, down, forward, or backward. Primary factor propelling the market growth includes the increasing prevalence of cervical dystonia. According to the National Organization for Rare Disorders, Inc. (NORD), an estimated 60,000 people in the US are suffering with cervical dystonia. Furthermore, the estimated prevalence ranges from 5 to 30 cases per 100,000 individuals around the globe. Owing to such factors, there is significant increase in the demand for effective treatments of cervical dystonia. Botulinum toxin injections/ medications are considered the most effective and well-tolerated treatment. However, there are several developments of new and innovative treatment such as deep brain stimulation (DBS), and stem cell therapy, gene therapy, among others.

Segmental Outlook

The global cervical dystonia treatment market is segmented based on drug type, application and end-user type. Based on drug type, the market is segmented into botulinum toxin, anticholinergic agents, dopaminergic agents, and others. Based on application, the market is sub-segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Based on end-user, the market is sub-segmented into hospitals, clinics and others. Among the application, the hospital pharmacy is expected to hold a considerable share of the market, as most of the drugs prescribed for the treatment of cervical dystonia are not authorized to sale such drugs.

Botulinum Toxin Drug Type to Dominate the Global Cervical Dystonia Treatment Market

Among the drug type, the botulinum toxin sub-segment is expected to hold a prominent share of the market. It is the most common type of drug used to treat cervical dystonia owing to its high efficacy and safety. Thus, there is continuous and steady development and approval activities for botulinum toxin drugs around the globe. For instance, in 2021, the US FDA approved a new botulinum toxin medication named Daxxify. It is a more potent botulinum toxin that has been shown to be more effective than older botulinum toxin medications in treating cervical dystonia. Such approval activities will lead to an increase in the adoption of botulinum toxin injections and medications as the effective treatment of cervical dystonia.

Regional outlooks

The global cervical dystonia treatment market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Among these, North America is expected to dominate the market, owing to the presence of well-established research institutes and hospitals for treatment of cervical dystonia.

European Region to Hold a Prominent Share of the Global Cervical Dystonia Market

Among all regions, the European region is anticipated to hold a considerable share of the global cervical dystonia market. The growth is primarily owing to the rising prevalence of cervical dystonia in the region. According to the Dystonia UK Organization, the most common dystonia is the neck dystonia, which affects around 18,000 adults in the UK. Resultantly, there is a considerable increase in the adoption of various strategic initiatives such as collaborations and mergers, among others to reduce the number of cervical dystonia across the region by providing effective treatment. For instance, in August 2023, IPSEN announced its collaboration with Dystonia Europe to help uncover the unmet needs of people living with cervical dystonia. The project included the co-creation of the first ever cervical dystonia patient experience map, published in the Orphanet Journal of Rare Disease, which charted the experiences of 15 people living with cervical dystonia in the UK, France and Italy, from initial diagnosis to living with the condition day-to-day.

Market Players Outlook

The major companies serving the global cervical dystonia treatment market include AbbVie Inc., Ipsen Pharma, Merz Pharma GmbH & Co.KGaA., Revance Therapeutics, Inc., Hint, Inc., and USWM, LLC among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in August, 2023 , the Food and Drug Administration approved Daxxify (DaxibotulinumtoxinA-lanm; Revance Therapeutics, Nashville, TN) for its first therapeutic indication for injection to treat cervical dystonia in adults.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global cervical dystonia treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. AbbVie Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Ipsen Pharma
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Merz Pharma GmbH & Co.KGaA.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Revance Therapeutics, Inc., Hint, Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. USWM, LLC
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Cervical Dystonia Treatment Market by Drug Type
    • 4.1.1. Botulinum Toxin
    • 4.1.2. Anticholinergic Agents
    • 4.1.3. Dopaminergic Agents
    • 4.1.4. Others
  • 4.2. Global Cervical Dystonia Treatment Market by Application
    • 4.2.1. Hospital Pharmacy
    • 4.2.2. Retail Pharmacy
    • 4.2.3. Online Pharmacy
    • 4.2.4. Others (Specialty Drug Stores)
  • 4.3. Global Cervical Dystonia Treatment Markey by End-User
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Others (Clinical Research Organizations)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Addex Pharma SA
  • 6.2. Akorn Inc
  • 6.3. Almirall, S.A.
  • 6.4. Apotex Inc.
  • 6.5. Astellas Pharma Inc.
  • 6.6. BIOGEN INC.
  • 6.7. Boehringer Ingelheim International GmbH
  • 6.8. Bristol Myers Squibb Co.
  • 6.9. DAIICHI SANKYO Co., Ltd.
  • 6.10. Dr. Reddy's Laboratories Ltd.
  • 6.11. Eisai Co., Ltd.
  • 6.12. Galderma S.A.
  • 6.13. H. Lundbeck A/S
  • 6.14. Johnson & Johnson Services, Inc.
  • 6.15. Kyowa Kirin Co., Ltd.
  • 6.16. Lannett Co., Inc.
  • 6.17. Mylan Pharmaceutical Pvt. Ltd.
  • 6.18. Novartis AG.
  • 6.19. Pfizer Inc.
  • 6.20. Piramal Grp.
  • 6.21. SANOFI
  • 6.22. Sumitomo Pharma Co., Ltd.
  • 6.23. Sun Pharmaceutical Ind., Ltd.
  • 6.24. Teva Pharmaceutical Ind., Ltd.
  • 6.25. UCB Biopharma SRL.

LIST OF TABLES

  • 1. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL CERVICAL DYSTONIA BOTULINUM TOXIN TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL CERVICAL DYSTONIA ANTICHOLINERGIC AGENTS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CERVICAL DYSTONIA DOPAMINERGIC AGENTS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL OTHER TYPE OF CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL CERVICAL DYSTONIA TREATMENT FOR RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CERVICAL DYSTONIA TREATMENT FOR ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 12. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CERVICAL DYSTONIA TREATMENT FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 20. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 24. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL CERVICAL DYSTONIA BOTULINUM TOXIN TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL CERVICAL DYSTONIA ANTICHOLINERGIC AGENTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CERVICAL DYSTONIA DOPAMINERGIC AGENTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL OTHER TYPE OF CERVICAL DYSTONIA TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY APPLICATION, 2022 VS 2030 ($ MILLION)
  • 7. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITAL PHARMACY MARKET SHARE BY REGION, 2022 VS. 2030 (%)
  • 8. GLOBAL CERVICAL DYSTONIA TREATMENT FOR RETAIL PHARMACY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CERVICAL DYSTONIA TREATMENT FOR ONLINE PHARMACY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY END-USER, 2022 VS 2030 ($ MILLION)
  • 12. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CERVICAL DYSTONIA TREATMENT FOR CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)